Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage